SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Holding Corp ICU.OQ reported a quarterly adjusted loss of 91 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.80. The mean expectation of two analysts for the quarter was for a loss of 97 cents per share. Wall Street expected results to range from $-1.03 to -91 cents per share.
Revenue rose 82% to $615.00 thousand from a year ago; analysts expected $486.50 thousand.
SeaStar Medical Holding Corp's reported EPS for the quarter was a loss of 91 cents.
The company reported a quarterly loss of $3.73 million.
SeaStar Medical Holding Corp shares had risen by 0.5% this quarter and gained 53.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 16.9% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $10.00, about 63.1% above its last closing price of $3.69
This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.97 | -0.91 | Beat |
Mar. 31 2026 | -0.82 | -0.90 | Missed |
Dec. 31 2025 | -1.06 | -0.80 | Beat |
Sep. 30 2025 | -1.50 | -1.30 | Beat |
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview